Combining Danone’s commitment to environmental stewardship with Zoetis’ expertise in animal genetics, the partnership aims to ...

Zoetis, a leader in veterinary healthcare, has consistently outperformed the market with robust revenue growth and strong margins, even during industry challenges. The company’s innovation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic ...

It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 1.4% in that time frame, underperforming the S&P 500. Will the recent positive trend continue ...

On the top line, sales could land at $16 billion, up 12.3% from the prior year. Zoetis (NYSE:ZTS) falls under the drug ...

This Zoetis 2021 business report presents the course of business throughout the respective business year. The report complies with the disclosure requirement for corporate entities and generally ...

Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling ...

Piper Sandler analyst David Westenberg maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $210.00. The company’s shares closed yesterday at $188.38.

To keep the lesson grounded in practicality, we'll use ROE to better understand Zoetis Inc. (NYSE:ZTS). Return on equity or ROE is a key measure used to assess how efficiently a company's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...